Bruttoergebnis Vom Umsatz Veränderung Datum
AbbVie USD 14.39B 1.85B 2026-06
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Amarin USD 23.17M 961K 2025-12
AstraZeneca USD 12.86B 251M 2026-06
BioCryst Pharmaceuticals USD 214.41M 61.36M 2026-06
DBV Technologies USD 2.77M 33.21M 2025-09
GlaxoSmithKline GBP 6.51B 757M 2026-06
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ionis Pharmaceuticals USD 265M 22M 2026-06
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 11.24B 1.18B 2026-06